Weleader Biomedical Co (ROCO:7713) FCF Yield %: 5.52 (As of Aug. 21, 2026) — 99% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
66 GF Score
Price NT$71.10
GF Value NT$74.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co FCF Yield %?

Weleader Biomedical Co ROCO:7713 +0.14% 66 FCF Yield % is 5.52 as of Aug. 21, 2026, which is 99% above its 10-year median of 2.77. GuruFocus rates ROCO:7713 with a GF Score™ of 66/100 and a GF Value™ of NT$74.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 84.57% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Weleader Biomedical Co's Trailing 12-Month Free Cash Flow is NT$179 Mil, and Market Cap is NT$3,234 Mil. Therefore, Weleader Biomedical Co's FCF Yield % for today is 5.52%.

The historical rank and industry rank for Weleader Biomedical Co's FCF Yield % or its related term are showing as below:

ROCO:7713' s FCF Yield % Range Over the Past 10 Years
Min: -0.05   Med: 2.77   Max: 5.53
Current: 5.52


During the past 6 years, the highest FCF Yield % of Weleader Biomedical Co was 5.53%. The lowest was -0.05%. And the median was 2.77%.

ROCO:7713's FCF Yield % is ranked better than
84.57% of 849 companies
in the Medical Devices & Instruments industry
Industry Median: -0.49 vs ROCO:7713: 5.52

Weleader Biomedical Co's FCF Margin % for the quarter that ended in Jun. 2026 was 20.62%.


Weleader Biomedical Co FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Weleader Biomedical Co FCF Yield % Related Terms


Weleader Biomedical Co FCF Yield % Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co FCF Yield % Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 3.22 2.98

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 -3.58 11.29 5.98 8.64

ROCO:7713 vs ABT, SYK, MDT: FCF Yield % Comparison

For the Medical Devices subindustry, Weleader Biomedical Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Weleader Biomedical Co FCF Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Weleader Biomedical Co's FCF Yield % falls into.


ROCO:7713
66GF Score
Weleader Biomedical Co Ltd ROCO:7713
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Weleader Biomedical Co's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=99.553 / 3338.1586
=2.98%

Weleader Biomedical Co's annualized FCF Yield % for the quarter that ended in Jun. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=69.924 * 4 / 3238.1048
=8.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of 5.52 mean?
Weleader Biomedical Co (ROCO:7713) has a FCF Yield % of 5.52 as of Aug. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Weleader Biomedical Co and its competitors. This is 99% above median its historical median of 2.77. According to the industry distribution chart, Weleader Biomedical Co ranks #131 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 15.4%.
Is Weleader Biomedical Co's FCF Yield % too high?
Weleader Biomedical Co's current FCF Yield % of 5.52 is 99% above median its 10-year median of 2.77. Based on the distribution chart, Weleader Biomedical Co ranks #131 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #131 out of 849 companies for FCF Yield %. This places Weleader Biomedical Co in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current FCF Yield % is 5.52, which is 99% above median its own 10-year median of 2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Weleader Biomedical Co (ROCO:7713) is currently considered Fairly Valued. The stock's GF Value™ is NT$74.60, compared to a current price of NT$71.10 — trading 4.7% below its estimated fair value. The current FCF Yield % is 5.52, which is 99% above median its 10-year median of 2.77. Weleader Biomedical Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current FCF Yield % is 5.52 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Weleader Biomedical Co (ROCO:7713) Overvalued in 2026?

Based on GuruFocus' analysis, Weleader Biomedical Co stock appears to be undervalued. The current stock price of NT$71.10 is trading 4.7% below its estimated GF Value™ of NT$74.60. GuruFocus considers Weleader Biomedical Co to be Fairly Valued.

Key valuation signals for ROCO:7713:

  • FCF Yield %: 5.52 (99% above median its 10-year median of 2.77)
  • GF Value™: NT$74.60 vs. price of NT$71.10 (4.7% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the ROCO:7713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
66GF Score

Get the complete analysis for ROCO:7713

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$71.10
Price
NT$74.60
GF Value